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Abstract 
Background Few studies of acute myocardial infarction (AMI) among hospitalized 
patients have had direct estimates of long-term case fatality after AMI, and the 
literature is conflicting regarding gender-related prognosis following AMI. Several 
revisions of the definition of AMI have complicated the analyses of trends in the 
number of AMI events and mortality.  
 
Aims To provide age and gender specific estimates of trends in short- and long-term 
case fatality for a first AMI of patients hospitalized, and to analyse the impact of 
applying five different definitions of AMI on number of AMI events, types and long-term 
mortality.   
 
Methods Paper I included patients hospitalized with a first AMI at Haukeland 
University Hospital during 1979-2001. Data were retrieved from The Western Norway 
Cardiovascular Registry and included additional data on long-term and all-cause death. 
The study period was divided into three periods and these were compared (p-trend). 
The clinicians used the WHO definition of AMI in the study period.  
Paper II and Paper III examined a different patient cohort, which was hospitalized for 
AMI (815 patients) during 1 March 2002 and 28 February 2003. The cohort also 
included 679 patients hospitalized in the same period with at least one measurement of 
elevated cardiac troponin I (cTnI) during the hospital stay, but not diagnosed with AMI.  
 
Results Paper I: The short- and long-term case fatality declined substantially during 
1979-2001 in 11878 patients hospitalized with a first AMI. The unadjusted 28-day case 
fatality declined from 31.1% to 19.8% in men and from 37.3% to 26.8% in women from 
the first period (1979-1985) compared with last period (1994-2001) (p-trend 
<0.0001). Landmark analysis showed continued decline in 1-10 year case fatality. Case 
fatality rates were significantly lower in women than men in patients >60 years.  
Paper II: The WHO 1979 definition of AMI with CK-MB mass as biomarker was used as 
reference and resulted in 566 definite AMIs among the 1494 total cohort of patients. 
When applying the ESC/ACC 2000, the AHA 2003, the Universal 2007 and the Universal 
2012 definition of AMI with troponin I as biomarker we observed approximately 30% 
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more AMI events.  The short- and long-term mortality were moderately higher applying 
the newer definitions.  
Paper III: Applying the Universal 2012 definition compared with the Universal 2007 
definition of AMI resulted in a minimal decrease in number of AMI events from 769 to 
760, with numbers of patients classified with Type 1, 2, 3, 4a, 4b and 5 AMI according to 
the Universal 2012 definition being 685, 27, 28, 13, 3 and 4 patients respectively.  
 
Conclusions There has been a substantial decline in short-term and long-term case 
fatality in patients hospitalized for a first AMI during 1979-2001. Women >60 years 
fare better than men do when we compare age-adjusted case-fatality rates. The number 
of AMI events depends on the definition of AMI and biomarker. When the WHO 1979 
definition of AMI was used as reference, we found that applying three newer definitions 
of AMI resulted in approximately 30% more patients diagnosed with definite AMI. Few 
patients classified as Type 2 AMI is specifically noticed. 
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List of definitions 
Case fatality rate 
The proportion of persons with a particular condition (cases) who die from that 
condition. The denominator is the number of incident cases; the numerator is the 
number of cause-specific deaths among those cases (1). 
 
Coronary artery disease 
Pathological processes of coronary arteries that may derive from a congenital 
abnormality, atherosclerotic, or non-atherosclerotic cause (2). In this dissertation, 
the term is used for atherosclerotic disease. 
 
Coronary heart disease 
An imbalance between myocardial functional requirements and the capacity of the 
coronary vessels to supply sufficient blood flow (2). It is a form of myocardial 
ischemia (insufficient blood supply to the heart muscle) caused by a decreased 
capacity of the coronary vessels. 
 
Landmark analysis 
An observational method used for comparing time-to-event outcome between 
groups determined during study follow-up. The goal of the landmark method is to 
estimate in an unbiased way the time-to-event probabilities in each group 
conditional on the group membership of patients at a specific time point, the 
landmark time (3). 
 
Mortality rate 
A measure of the frequency of occurrence of death in a defined population during a 
specified interval of time (1). 
 
Myocardial infarction 
Necrosis of the myocardium caused by an obstruction of the blood supply to the 
heart (coronary circulation) (2). 
 
Risk factor 
An aspect of personal behaviour or lifestyle, environmental exposure, or inborn or 
inherited characteristic, which, on the basis of epidemiologic evidence, is known to 
be associated with a health-related condition considered important to prevent (2). 
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1. Introduction of acute myocardial infarction 
1.1 Historical perspectives 
Initial description and treatment 
“But there is a disorder of the breast marked with strong and peculiar symptoms, 
considerable for the kind of danger belonging to it, and not extremely rare, which 
deserves to be mentioned more at length. The seat of it, and sense of strangling, and 
anxiety with which it is attended, may make it not improperly be called angina 
pectoris.” 
After William Heberden’s classic description of angina pectoris in 1772, it took more 
than a century before pathologist Ludvig Hektoen in 1879 concluded that myocardial 
infarction is caused by coronary thrombosis secondary to sclerotic changes in the 
coronaries (4-6). 
In 1910, the Russian clinicians Obrastzov and Straschesko published the first 
description of a nonfatal myocardial infarction (7). Two years later James B. Herrick 
published a paper, informing the American physicians about the symptoms of heart 
infarction based on the Russian paper (8). He further stimulated clinical use of the 
electrocardiogram as a diagnostic tool, and he emphasized “total bed rest” as the 
treatment for acute myocardial infarction (AMI). These approaches were standard care 
of patients with AMI until the beginning of the 1950s. Hospital mortality was high, 
more than 30%, and only morphine, and later diuretics and anticoagulants were used 
(9;10). 
 
Initial epidemiological observations 
The previous century can be roughly divided into two concerning the overall incidence 
of disease in Western countries. Infections dominated before 1950, and in the second 
half cardiovascular disease and cancer became leading causes of illness and death (11).  
In the United States an increase of coronary mortality among middle aged men was 
observed already during the 1930-40s (12). This was the background of the 
Framingham Heart study, established by the National Heart Institute in 1947, with 
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close collaboration between clinical cardiology, biostatistics and epidemiology (13). 
Their first findings indicated that elevation in blood pressure and cholesterol levels 
were associated with an increased incidence of ischemic heart disease and AMI (14). 
The identification of coronary risk factors resulted in emphasis on prevention (15-19). 
 
In Norway the Department of the Interior established a cause of death register already 
in 1853, with relatively reliable statistics from approximately year 1900 (11). Incidence 
and death rates among Norwegian patients with cardiovascular diseases increased 
moderately in the beginning of the 1900th century (20;21).  Mortality due to coronary 
disease was relatively similar in men and women, with a decline in both genders during 
1940-45 (21). However, from 1950 until today there has been a significant gender 
difference regarding mortality from AMI and ischemic heart disease (22-25). When 
comparing mortality rates in Figure 1 we observe an increase of 130% in men and 60% 
in women aged 45-64 years in the period 1966-70 compared with 1951-55. After the 
peak, there was a steady decline in mortality to a lower level than in 1951-55, and the 
mortality rates for men and women have again approached each other. 
 
 
Figure 1: Mortality from myocardial infarction and other ischemic heart disease in men and 
women aged 45-64 years. Deaths per 100000 inhabitants, age standardized. Source: Cause of 
Death Register. Statistics Norway. (http://www.fhi.no/eway/) 
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Discovery of risk factors 
Strøm and Jensen described a decrease of cardiovascular and coronary morbidity 
during World War II (21). Their hypothesis was that the cause of reduced mortality was 
a reduction of saturated fat in the diet and a decrease in smoking. They also assumed 
that the rapid change in mortality probably was due to change in the tendency of 
coronary thrombosis rather than atherosclerosis.  In 1962 the combined results of the 
Framingham and Albany studies were published, documenting strong relationship 
between smoking and the incidence of myocardial infarction (17). Other major risk 
factors as hypertension, high serum cholesterol, diabetes mellitus and advancing age 
have been studied at Framingham and in other studies such as the Interheart study 
(26-30). 
 
Establishment of coronary units and acute treatment 
In the 1960s coronary care units were established in many hospitals to monitor AMI 
patients, and ventricular fibrillation could be treated with resuscitation and 
defibrillation which reduced hospital mortality significantly (31). By the 1970s, in-
hospital mortality from AMI dropped to approximately 15% among patients treated in 
coronary care units. Beta-blockers and nitroglycerine were given during acute attacks 
and active rehabilitation was introduced (32). The reperfusion era evolved in the 1980s 
and the GISSI trial (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto 
Miocardico) demonstrated in 1986 that intravenous streptokinase reduced early 
mortality in patients with ST-segment elevation myocardial infarction (STEMI) (33). 
The ISIS-2 study (Second International Study of Infarct survival) showed that the 
combination of streptokinase and aspirin led to further reduction in mortality (34).   
 
The field of invasive cardiology emerged after Andreas Grüntzig performed the first 
balloon angioplasty in 1977 (35). The initial technique was followed by the insertion of 
stents, and further drug-eluting stents to prevent coronary restenosis. The treatment 
with primary percutaneous coronary intervention (PCI) developed during the 1990s, 
and since year 2000 most Western countries have established PCI-centres with acute 
treatment of STEMI. Among selected patients who have undergone PCI within six hours 
after symptom onset, studies have shown in-hospital mortality as low as 3-5% (36;37). 
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The efficacy of acute reperfusion also depends on public and professional education 
programs, and the development of ambulance services with a short interval between 
onset of symptoms and the patient’s arrival at the hospital (38;39). Although mortality 
among unselected patients with AMI also is decreasing significantly, the in-hospital 
mortality is still 7-15% (40-42). 
 
Secondary prevention 
The Survival and Ventricular Enlargement (SAVE) trial demonstrated that long-term 
treatment with angiotensin-converting-enzyme (ACE)-inhibitors reduced mortality 
among patients with left ventricular dysfunction after AMI (43). The LDL-cholesterol 
pathway was delineated in the 1970s, and the HMG-CoA reductase inhibitors (statins) 
appeared to selectively lower LDL-cholesterol in plasma (44;45). The 4S study and 
several other clinical studies demonstrated that statin treatment reduces the risk of 
AMI and prolong life (46;47). 
 
Primary prevention 
The epidemic wave of cardiovascular disease and AMI in the Western world during 
1960-1970 combined with documentation of risk factors resulted in further research 
on the effect of reducing risk factors. The Oslo study showed a significant effect of diet 
and smoking intervention on the incidence of myocardial infarction (48). Different risk 
charts have been used in clinical practice, and studies have shown that primary 
prevention can explain approximately 50% of the decline in AMI seen in the recent 
decades (49;50). 
 
Epidemiology in recent years 
The reductions of risk factors and advances in treatment have contributed to the 
reduction of coronary deaths in the Norway over the past 40 years (23;24;51;52). We 
have changed status from a high-risk to a low-risk country at the same level as the 
Mediterranean countries (Figure 2). Figure 2 further illustrate some of the known 
north-east to south-west gradient in mortality from AMI among European countries 
(53;54). Studies have revealed lowest mortality rates due to AMI for both women and 
men in Spain, France, Italy and Switzerland and highest rates in Central and East 
Europe such as Bulgaria or the Russian Federation. 
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Figure 2: Deaths due to myocardial infarction in Croatia, Estonia, Finland, France, Greece, 
Norway, Poland and the Russian Federation 1970-2012, all age group. Per 100000 inhabitants. 
Source: WHO, European HFA Database, July 2013. (http://data.euro.who.int/hfadb/) 
 
Cardiovascular disease is still the leading cause of death worldwide, with AMI as the 
most important contributor (55).  The global burden of coronary disease is expected to 
increase due to tobacco use, unhealthful food, decreased physical activity and a longer 
average life span in the middle- and low-income countries (56). Although the Western 
world has seen the epidemic wave of AMI decline in recent years, recent papers 
demonstrate a slight increasing hospitalizations rate of AMI in younger age groups 
(52;57;58).  
 
 
Croatia 
Estonia 
Russian Federation 
Greece 
Norway 
Poland 
Finland 
France 
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1.2 Definitions  
The first WHO 1959 definition and other early definitions 
The definition of acute myocardial infarction (AMI) was introduced by the World 
Health Organization (WHO) in 1959 with emphasis on chest pain and changes in 
successive ECGs (Table 1) (59). It was followed by reports from American Heart 
Association (AHA) in 1964 and the WHO in 1971, and the Framingham study provided 
further specifications (60-62). The diagnosis of AMI was based on the presence of at 
least two of three criteria: typical symptoms, typical ECG abnormalities and increase in 
enzymes indicating myocardial injury. WHO revised the diagnosis of ischemic heart 
disease in 1979 (WHO 1979 definition) with introduction of definite and possible AMI 
(63). In epidemiological studies there had been variation and inconsistency in the 
populations and in definition of AMI used. This was the background for the WHO 
MONICA project (Multinational MONItoring of trends and determinants in 
Cardiovascular disease), with the objective to measure the trends in cardiovascular 
mortality and incident coronary heart disease (CHD), classifying the events into five 
categories, related to risk factors (64-67). 
 
The ESC/ACC 2000 definition 
The requirement for a more precise definition of AMI resulted in the redefinition of 
AMI from the European Society of Cardiology (ESC) and American College of Cardiology 
(ACC) published in year 2000 (ESC/ACC 2000 definition) (68). This definition includes 
only the definite category of AMI, which may lead to underestimation of the incidence 
of AMI in epidemiological studies. The ESC/ACC was criticised for changing the 
definition of AMI, first because of problems with comparisons with previous definitions 
and populations, secondly because of lack of a group of sudden cardiac death (69;70). A 
problem regarding the interpretation of troponin included in this definition was “a 
typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of 
biochemical markers of myocardial necrosis”. In clinical practice a sufficient number of 
troponin values are often lacking, and many researchers and clinicians accepted 
troponin “rise or fall” as the diagnostic criterion (71;72). 
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The AHA 2003 definition 
In 2003, epidemiological researchers from AHA, World Heart Federation (WHF), ESC, 
Centers for Disease Control and prevention (CDC) and the National Heart, Lung and 
Blood Institute (NHLBI) published an AHA scientific statement (AHA 2003 definition) 
to address the specific needs of population surveillance (73).  
 
The Universal 2007 definition 
Later, the ESC, ACC, AHA and WHF published the Universal 2007 definition which 
addressed several of the weaknesses of the 2000 definition (74). The Universal 2007 
definition included five new categories of AMI. Minor changes in the ECG criteria for 
AMI were introduced. 
 
The WHO 2009 revision  
The WHO 2009 revision of the definition of AMI acknowledged that the new 
biomarkers and even ECG equipment are often not available in low-income countries 
(75).  The “Universal” definition of AMI is not applicable in these countries. The WHO 
2009 definition of AMI is divided in three categories; Category A is identical with the 
Universal 2007 definition, Category B is applied when the information of cardiac 
biomarkers is incomplete together with ischemic symptoms and development of 
pathological Q-waves. Category C (probable MI) is applied in persons with ischemic 
symptoms, when either ECG changes are suggestive of MI, or the information on cardiac 
biomarkers is incomplete. 
  
The Universal 2012 definition  
The Universal 20012 definition of myocardial infarction was developed as a result of 
the new generations of troponin which have become increasingly sensitive to 
myocardial injury (76). As compared with the Universal 2007 definition the Universal 
2012 definition requires a higher troponin threshold for Type 4a (PCI) and Type 5 
(CABG), and additional symptoms or signs for Type 4a AMI. The new definition seeks to 
further clarify the difference between AMI and myocardial injury.  
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Table 1 Main criteria and change in the definition of acute myocardial infarction 
Definition Fundamental criteria Change Subgroups 
First WHO 1959 
definition 
History of myocardial infarction 
and changes in successive ECGs 
  
WHO 1979 
definition 
Definite AMI: Unequivocal ECG 
changes and/or unequivocal 
enzyme changes, history typical 
or atypical.  
Possible AMI: Serial equivocal 
ECG changes >24 hours, +/- 
unequivocal enzyme changes. 
History typical or atypical 
Enzymes added. Division in 
definite and possible AMI 
Definite 
Possible 
WHO MONICA 
1983 definition 
WHO 1979 definition and the 
Minnesota codes for ECG from 
US studies 
Comprehensive 
classification for 
epidemiology 
Definite 
Possible 
Ischemic cardiac arrest 
No AMI or coronary death 
Unclassifiable 
ESC/ACC 2000 
definition 
“Rise and fall”  
Typical rise and gradual fall of 
troponin or CK-MB with at least 
one of the following: Ischemic 
symptoms, new pathologic Q-
wave, ST-elevation or ST-
depression, PCI or AMI at 
autopsy 
Biomarkers a new crucial 
role 
Definite 
ESC/ACC 2000 
definition  
“Rise or fall”  
Most clinicians and researchers 
interpreted the –ESC/ACC 2000 
def. as: “ Typical rise or gradual 
fall of troponin or CK-MB” 
Alternative interpretation of 
the ESC/ACC 2000 
definition 
Definite 
AHA 2003 
definition (AHA, 
WHF, ESC, CDC, 
NHLBI) 
The ESC/ACC 2000 def. with 
rise or fall of troponin or CK-
MB. The classification of ECG 
and biomarkers defined as 
diagnostic, equivocal, missing or 
normal. Cardiac symptoms and 
signs present or absent 
Implementing officially the 
“rise or fall” of Troponin or 
CK-MB. For 
epidemiological surveillance 
Definite  
Probable 
Possible 
Universal 2007 
definition (ESC, 
ACC, 
AHA,WHF) 
The ESC/ACC 2000 def. with a 
“rise or fall” of troponin/CK-
MB.  
Including sudden cardiac 
death 
Changes in ECG-def: V1-3 
and T-inversion 
5 subtypes of AMI 
x Type 1  “Spontaneous” 
x Type 2  “Secondary” 
x Type 3  “Death” 
x Type 4a “PCI” 
x Type 4b “Stent-thrombus” 
x Type 5   “CABG” 
WHO 2009 
definition 
The WHO MONICA 1981 
definition and the Universal 
2007 definition 
 
Three categories, include 
settings with small 
resources, 
and the category of probable 
AMI 
Category A: Identical with the 
Universal 2007 definition 
Category B: Biomarkers are 
incomplete, ischemic symptoms and 
pathological Q-waves 
Category C (probable MI): Ischemic 
symptoms, when either ECG changes 
are suggestive of MI or incomplete 
information on biomarkers 
Universal 2012 
definition  
(ESC, ACC, 
AHA, WHF) 
The ESC/ACC 2007 definition 
with a “rise or fall” of 
troponin/CK-MB.  
Higher troponin cut-off 
values for PCI and CABG 
related AMI, and demand of 
symptoms or clinical 
findings (Type 4a) 
Changes in ECG-def: V2-3 
for men <40 year 
x Type 1  “Spontaneous” 
x Type 2  “Secondary” 
x Type 3  “Death” 
x Type 4a “PCI” 
x Type 4b “Stent-thrombus” 
x Type 4c “Restenosis” 
x Type 5   “CABG” 
ACC: American College of Cardiology; AHA: American Heart Association; AMI: Acute myocardial infarction; CABG: 
Coronary artery bypass graft; CDC: Centers for Disease Control and prevention; CK-MB: Creatine kinase myoglobin; cTnI: 
cardiac Troponin I; ECG: Electro cardiogram; ESC: European Society of Cardiology; NHLBI: National Heart, Lung and 
Blood Institute; MONICA: Multinational MONItoring of trends and determinants in Cardiovascular disease; PCI: 
Percutaneous coronary intervention; WHF: World Heart Federation; WHO: World Health Organisation. 
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1.3 Symptoms 
The WHO 1959 definition  
The WHO 1959 definition of AMI described the symptoms of myocardial infarction as: 
“a gradual, or more often, a sudden onset of severe chest pain, similar to that of definite 
angina of effort. The pain may have been associated with symptoms of collapse and/or 
other symptoms, often serious enough to require prolonged bed-rest at home or in 
hospital”  (59). The definite angina pectoris is described as: “A pain occurring centrally 
in the front of the chest at the mid- or upper- sternal level brought on by effort (e.g. 
exercise, emotional stress, ingestion of food, or exposure to cold). 
 
The WHO 1979 definition 
In the revised WHO 1979 definition of AMI history was briefly described as: “The 
history is typical if severe and prolonged chest pain is present: Sometimes the history is 
atypical and the pain may be mild or even absent, or other symptoms may 
predominate” (63). 
 
The WHO MONICA definition 
The WHO MONICA project developed a comprehensive definition of AMI for 
epidemiological studies (64;66). Typical symptoms were described as “When chest 
pain is present and characterized by duration of more than 20 minutes and without 
definite noncardiac or cardiac nonatherosclerotic cause”. Atypical symptoms were 
described as “If symptoms were not typical but there was one or more of atypical pain, 
acute left ventricular failure, shock and syncope, and the absence of cardiac disease 
other than ischemic heart disease, and no definite noncardiac or cardiac 
nonatherosclerotic cause”. The WHO MONICA project further classified; other 
symptoms, no symptoms, inadequately described symptoms and insufficient data. 
 
The ESC/ACC 2000 definition 
According to the ESC/ACC 2000 definition of AMI possible ischemic symptoms “include 
chest, epigastric, arm, wrist or jaw discomfort with exertion or at rest. The discomfort 
associated with AMI usually lasts at least 20 minutes, but may be shorter in duration. 
The discomfort may develop in the central or left chest and then radiate to the arm, jaw, 
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back or shoulder. The discomfort is usually not sharp or highly localized and may be 
associated with dyspnea, diaphoresis (excess sweating), nausea, vomiting or light-
headedness (68).” Further; “The discomfort is not affected by moving the muscles of 
the region where the discomfort is localized, nor is it worsened by deep inspiration.” 
 
The AHA 2003 definition 
The AHA 2003 definition of AMI described cardiac symptoms as: “Presence of acute 
chest, epigastric, neck, jaw, or arm pain or discomfort or pressure without apparent 
noncardiac source. More general, atypical symptoms, such as fatigue, nausea, vomiting, 
diaphoresis, faintness, and back pain, should not be used as a diagnostic criterion, 
although they are clinically useful in arriving at the correct diagnosis” (73). Cardiac 
signs: “Acute congestive heart failure or cardiogenic shock in the absence of non-CHD 
causes”. 
 
The Universal 2007 definition 
The Universal 2007 definition of AMI describes possible ischaemic symptoms as: 
“Various combinations of chest, upper extremity, jaw or epigastric discomfort with 
exertion or at rest. The discomfort associated with AMI usually last at least 20 minutes. 
Often, the discomfort is diffuse, not localized, not positional, not affected by movement 
of the region, and it may be accompanied by dyspnoea, diaphoresis, nausea, or syncope. 
These symptoms are not specific to myocardial ischaemia and can be misdiagnosed and 
thus attributed to gastrointestinal, neurological, pulmonary, or musculoskeletal 
disorders. Myocardial infarction may occur with atypical symptoms, or even without 
symptoms, being detected only by ECG, biomarker elevation, or cardiac imaging (74).” 
 
The WHO 20009 and the Universal 2012 definitions 
The WHO 2009 definition and the Universal 2012 definition of AMI adopted the 
symptoms criteria from the Universal 2007 definition (75;76). 
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1.4 ECG 
The WHO 1959 definition 
The WHO 1959 definition of AMI divided the ECG changes in two; those considered to 
be diagnostic of “very probable” (Q-waves) and “possible” (transient ST-elevation or 
ST–depression) myocardial infarction (59). The ECG changes were illustrated to clarify 
the description, as seen in these two examples: 
 
 
 
Figure 3 Classification and criteria for epidemiological studies. WHO 1959 (59).   
 
The WHO 1979 definition  
The WHO 1979 definition of AMI described ECG as:  
1. Unequivocal changes 
 “Unequivocal changes in ECG are the development of abnormal, persistent Q or QS 
waves, and evolving injury current lasting longer than 1 day. When the ECG shows 
these unequivocal changes, the diagnosis may be made on the ECG alone” (63). 
2. Equivocal changes 
“In other cases, the ECG may show equivocal changes, consisting of  
a) Stationary injury current,  
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b) Symmetrical inversion of the T wave,  
c) Pathological Q wave in single ECG record, or  
d) Conduction disturbances.” 
 
The WHO MONICA definition 
The WHO MONICA project classified ECGs according to the Minnesota code manual of 
ECG findings in a very accurate way (64). However, we have not used this classification 
in our studies. 
Code 1: Definite ECG 
(A) The development in serial records of a diagnostic Q-wave (with subsections 1.1-1.7) 
And/or 
(B) The evolution of an Injury current that lasts more than 1 day  
Code 2: Probable ECG: Evolution of repolarization changes 
Code 3: Ischemic ECG (in one or more records) 
Code 4: Other ECG 
Code 5: Uncodable ECG 
Code 9: ECG absent 
 
The ESC/ACC 2000 definition 
The ESC/ACC 2000 definition of AMI states that ST-changes and T-inversion reflect 
myocardial ischemia and that the diagnosis of AMI additionally requires an increase in 
troponin (68). 
ECG changes that may progress to myocardial infarction: 
1. “Patients with ST segment elevation: 
New or presumed new ST segment elevation at the J point in two or more contiguous 
leads with the cut-off points >0.2 mV in leads V1, V2 or V3 and >0.1 mV in other leads 
(contiguity in the frontal plane is defined by the lead sequence aVL, I, inverted aVR, II, 
aVF, III) 
2. Patients without ST segment elevation: 
a. ST segment depression 
b. T wave abnormalities only 
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New or presumed new ST segment depression or T wave abnormalities, or both, should 
be observed in two or more contiguous leads. Also, new or presumed new symmetric 
inversion of T waves >1 mm should be present in at least two contiguous leads.” 
 
Electrocardiographic changes in established myocardial infarction, in absence of QRS 
confounders (left bundle branch block, left ventricular hypertrophy, Wolff-Parkinson-
White syndrome): 
“Any QR wave in leads V1 through V3 >30 ms (0.03 s); abnormal Q wave in lead I, II, aVL, 
aVF or V4 through V6 in any two contiguous leads and at least 1 mm in depth. New Q 
waves in the presence of left bundle branch block should be considered as pathologic.” 
 
The AHA 2003 definition 
The AHA 2003 definition of AMI follows the WHO MONICA project when applying the 
Minnesota ECG coding (73). The ECGs is divided into four categories: 
A. Evolving diagnostic ECG 
B. Positive ECG 
C. Nonspecific ECG 
D. ECG negative for ischemia 
The categories are supplied with exact description of every possible variation of ECG 
changes. 
 
The Universal 2007 definition 
The Universal 2007 definition of AMI is based on the ESC/ACC 2000 definition, but is 
more specific in its description of the ECG (74). There are two new amendments: 
1. The limit for ST-elevation in V2-3 is now >0.15 mV among women (instead of >0.2 
mV) 
2. New horizontal or down-sloping ST-depression >0.05 mV (instead of >0.1 mV) 
 
The WHO 2009 definition 
The WHO 2009 definition follows the ECG interpretation according to the Minnesota 
code (75).   
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The Universal 2012 definition 
The Universal 2012 definition of AMI is almost identical to the Universal 2007 
definition regarding the ECG interpretation (76). However, the cut off for ST-elevation 
in V2-3 is now >0.25 mV in men <40 years (instead of >0.20 mV). 
 
1.5 Biomarkers 
When myocytes die in connection with AMI, protein inside the cell will be released. The 
blood flow in the area of infarction is occluded and most of the proteins reach the blood 
via the lymphatics, and appear in blood after some degradation (77). Diffusion rate is 
determined by molecular size and molecular weight; hence the biomarkers with 
smallest molecular weight diffuse out of the necrotic region most rapidly. 
 
Aspartate transaminase 
The first practical test introduced for myocardial necrosis was Aspartate transaminase 
(AST or ASAT), also called serum glutamin oxaloacetic transaminase (SGOT), which is 
an important enzyme in the amino acid metabolism. AST was defined as a biochemical 
marker for the diagnosis of AMI in 1954 (78).  
 
Lactate dehydrogenase  
Lactate dehydrogenase (LD or LDH) is found in many body tissues as blood cells and 
heart, a main function of LD is to catalyse the conversion of pyruvate to lactate and 
back. LD has five isoenzymes, LDH-1 is predominant in the heart and red blood cells 
and LDH-5 is the major isoenzyme of skeletal muscle and liver. LD is normally present 
in a small amount and can be measured as a surrogate marker for tissue breakdown as 
in AMI (79). 
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Table 2 Types of cardiac biomarkers 
Biomarker Molecula
r 
Weight 
(kDa) 
Elevated 
after AMI 
(hours) 
Peak 
after 
AMI 
Normal 
after 
(days) 
Description 
Aspartate 
transaminase 
(AST) 
90  12 h 1-2 
days 
3-5 d Defined as a marker of cardiac 
damage in 1954. Not specific for 
heart, also a marker of liver 
damage 
Lactate 
dehydrogenase 
(LD or LDH) 
140  18 h 2-3 
days 
7 d In many body tissues as heart, 
blood cells, skeletal muscle and 
liver 
Creatine 
kinase (CK) 
86  4-6 h 24 h 2-3 d Found in heart, brain and skeletal 
muscle 
Creatine 
kinase 
isoenzyme 
MB (CK-MB)  
86 4-9 h 10-24 h 1-3 d Relatively specific for heart 
damage when damage of skeletal 
muscle is not present 
Myoglobin 18 1-3 h 4-12 h 1 d Low specificity (60-90%). Rarely 
used in clinical practice 
Troponin I 
 
 
 
24 3-6 h 12-24 h 7-14 d Only in cardiac tissue.  
 
Troponin I and troponin T are 
more specific markers for 
myocardial damage and hence 
superior to CK-MB. 
 
Elevated cTnT may in some cases 
be due to foetal cTnT in diseased 
and regenerating skeletal muscle.  
Troponin T 35 3-6 h 12-24 h 7-14 d 
kDa: kilo Dalton, h: hour, d: day 
 
Creatine kinase  
Creatine kinase (CK) is an enzyme which catalyses creatinine and consumes adenosine 
triphosphate (ATP) to create phosphocreatine and adenosine diphosphate (ADP). This 
enzyme reaction is reversible and ATP can be generated from phosphocreatine and 
ADP. In cells that consume ATP rapidly as skeletal muscle, but also heart and brain, 
phosphocreatine serves as an energy reservoir for rapid buffering and regeneration of 
ATP on the spot (80). CK is an important enzyme in such tissues, and was introduced in 
the diagnostic of AMI in the middle of the 1960s (81;82).  
 
Myoglobin 
Myoglobin is an oxygen-binding protein, with high concentration in both skeletal and 
heart muscle (83). Myoglobin has been rarely used in clinical practice due to its low 
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specificity (60-90%), and has not been used in our studies. However, myoglobin is 
potentially useful for ruling out but not for confirming the AMI diagnosis. 
 
 
Figure 4 Typical rise and fall of cardiac biomarkers following myocardial infarction. Modified 
from Lewandrowski, K. et al. (84) 
 
Creatine kinase isoenzyme (CK-MB) 
CK enzymes consist of B (brain type) or M (muscle type), and there are three different 
isoenzymes: CK-MM, CK-BB and CK-MB. The heart expresses CK-MB at 25-30% and CK-
MM at 70%. However, the skeletal muscle expresses CK-MB at 1% and CK-MM at 98%. 
Normal activity in serum is almost entirely from the CK-MM, and the CK-MB in normal 
serum is usually undetectable. Serum CK-MB activity >5% of total is considered 
diagnostic for AMI. The determination of CK isoenzymes as a marker for AMI was 
introduced in the early 1970s (85). CK-MB were measured by labour-intensive 
electrophoretic techniques, and was replaced by automated CK-MB mass assays during 
the mid-1990s, which performed testing faster, more frequently and at a lower cost. 
 
Troponin 
Troponin is a complex of three regulatory proteins in both cardiac and skeletal 
muscles: 
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x Troponin C – the calcium binding component 
x Troponin I (24 kDa) – the inhibitory component – binding of actin 
x Troponin T (35 kDa) - the tropomyosin binding component 
Together with myosin and actin the troponin complex forms the contractile part of the 
musculature (86). Cardiac troponin I (cTnI) is exclusively found in cardiac tissue. 
However, cardiac troponin T (cTnT) is found in a foetal form in diseased and 
regenerating skeletal muscle, and there is an ongoing discussion if new generations of 
cTnT assays avoid detection of foetal cTnT or not (87;88). The cTnI and cTnT can be 
detected by assays of monoclonal antibodies directed against heart specific antigen 
(89). Troponin is released during AMI from the cytosolic pool of the myocytes. Its 
subsequent release is prolonged with degradation of actin and myosin filaments. 
Differential diagnosis of troponin elevation includes acute infarction, severe pulmonary 
embolism, heart failure, myocarditis and several other medical conditions. Analysis of 
troponins can also be used to calculate infarct size, but the peak level must be 
measured day 3-4 after the onset of AMI   (90). 
 
 
 
Figure 5: Evolving methods of cardiac biomarkers and changing definitions of acute 
myocardial infarction. Modified from Alpert, JS et al. (91). 
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1.6 Imaging techniques 
Cardiac imaging techniques were introduced with the Universal 2007 definition and 
continued with the Universal 2012 definition of AMI as a diagnostic criteria in line with 
symptoms and ECG changes; “Imaging evidence of new loss of viable myocardium or 
new regional wall motion abnormality” (74;76).  Echocardiography, computed 
tomography (CT) and magnetic resonance imaging (MRI) have been increasingly used 
in the setting of acute coronary syndrome (ACS) in recent years (92;93). Since our 
patient’s cohorts were included until 2003, imaging techniques were not included in 
the AMI definitions at that time and we have not used this criterion in our studies. 
 
1.7 Elevation of cardiac troponin without AMI 
The Universal 2007 definition of AMI and the Universal 2012 definition emphasize that 
troponin elevation alone is never sufficient to diagnose AMI. This is specified in the 
criteria for AMI; “the term myocardial infarction should be used when there is evidence 
of myocardial necrosis in a clinical setting consistent with myocardial ischaemia” 
(74;76). Rise and/or fall of cardiac biomarkers (preferably troponin) together with at 
least one of the following are required; symptoms of ischemia, ECG changes indicative 
of new ischemia, imaging evidence of a new AMI or identification of an intracoronary 
thrombus by angiography or autopsy. The Universal 2012 definition of AMI introduces 
the term “myocardial injury”, defined as cell death marked by cardiac troponin 
elevation. Table 3, modified from the consensus document of the Universal 2012 
definition of AMI, include conditions related to AMI and conditions not related to AMI: 
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Table 3 Causes of elevation of cardiac troponin values due to myocardial injury 
Injury related to primary myocardial ischaemia 
Plaque rupture 
Intraluminal coronary artery thrombus formation 
Injury related to supply/demand imbalance of myocardial ischaemia 
Tachy-/brady-arrhythmias 
Aortic dissection or severe aortic valve disease 
Hypertrophic cardiomyopathy 
Cardiogenic, hypovolemic, or septic shock 
Severe respiratory failure 
Severe anaemia 
Hypertension with or without left ventricular hypertrophy  
Coronary spasm 
Coronary embolism or  vasculitis 
Coronary endothelial dysfunction without significant coronary artery disease 
Injury not related to myocardial ischaemia 
Cardiac contusion, surgery, ablation, pacing, or defibrillator shocks 
Rhabdomyolyse with cardiac involvement 
Myocarditis 
Cardiotoxic agents, e.g. anthracyclines, trastuzumab 
Multifactorial or indeterminate myocardial injury 
Heart failure 
Stress (Takotsubo) cardiomyopathy 
Severe pulmonary embolism or pulmonary hypertension 
Sepsis or critical ill patients 
Renal failure 
Severe acute neurological diseases, e.g. stroke, subarachnoid haemorrhage 
Infiltrative diseases, e.g. amyloidosis, sarcoidosis 
Strenuous exercise 
Modified from Thygesen, K. et al (76) 
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2. Aims of the present study 
Main Aims 
To provide age and gender specific estimates of trends in short- and long-term case 
fatality for a first AMI of hospitalized patients, and to analyse the impact of applying 
five different definitions of AMI on number of AMI events, types and long-term 
mortality.   
 
Specific Aims 
1. To investigate age and gender specific  time trends in short- and long-term case 
fatality up to 10 years among patients hospitalized with a first AMI at Haukeland 
University Hospital during 1979-2001. 
 
2. Study the impact of applying four different definitions of AMI on the number and 
types of AMI events and long-term mortality. 
 
3. To compare the most recent Universal 2012 definition of AMI to the previous 
definition with respect to number and types of AMI events. Further to study the 
short- and long-term all-cause mortality. 
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3. Methods 
 
3.1 Study populations 
Paper I  
We examined patients with a first AMI (I21) admitted to Haukeland University Hospital 
between 1 January 1979 and 31 December 2001. The patient data were obtained from 
the Western Norway Cardiovascular Registry (WENOCARD), a regional registry of all 
patients with cardiovascular diagnoses and procedures recorded in the hospital 
discharge and administrative system in Western Norway. WENOCARD was later 
included in the Norwegian Cardiovascular Disease Registry (NorCVD), and contains 
data from Haukeland University Hospital from 1 January 1972.  
 
Paper II and Paper III  
We retrospectively studied patients hospitalised at Haukeland University Hospital 
during the period 1 March 2002 through 28 February 2003. Eligible patients were men 
and women of all ages, with either a discharge diagnosis of a first (I 21) or recurrent (I 
22) AMI, or without any discharge diagnosis of AMI but with at least one measurement 
of elevated cardiac troponin I (cTnI) during the hospital stay.   
 
3.2 Clinical data 
Symptoms 
Paper I 
The clinicians applied the WHO definition of AMI  with presence of at least two of three 
criteria: Typical symptoms, typical ECG abnormalities and increase in enzymes 
indicating myocardial injury (63). Enzyme changes included serum alanin 
aminotransferase, aspartate aminotransferase, creatine kinase and CK-MB.  Troponin I 
was not officially implemented in the diagnostic criteria at the hospital until after the 
study period. The ECGs were interpreted by clinicians at the hospital without 
subsequent validation. For coding, the International Classification of Diseases ICD-8 
and ICD-9 (410) were used through 1998, and ICD-10 (I21 or I22) from 1999.   
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Paper II and Paper III 
The patients’ medical records were examined for information on symptoms, ECG, 
cardiac biomarkers, comorbidity, coronary risk factors and treatment during the 
hospital stay. Discomfort or pain in the chest, upper extremity, jaw or epigastriae 
lasting for >20 minutes were interpreted as ischemic symptoms. 
 
Cardiac biomarkers 
Paper II and Paper III 
Patients with suspected acute coronary syndrome at admission or during the 
hospitalization had a blood sample drawn for measurements of CK-MB mass and cTnI 
levels as soon as possible and 6-9 hours later. If at least one of the biomarkers was 
elevated, a third sample was collected at least 12 hours after the second sample. In 
addition blood samples were routinely drawn from patients treated with PCI or CABG. 
CK-MB mass level values were classified according to the WHO-1979 definition, which 
describes unequivocal enzymes change as serial change, or initial rise and subsequent 
fall. CK-MB mass was not used in Paper III. 
 
The level of cTnI was measured using the Bayer Technicon Immuno assay, with a 
decision limit at cTnI >0.10 Pg/L according to the 99th percentile of a healthy 
population (94). However, acceptable imprecision of troponin assays is a CV <10% at 
the 99th percentile reference limit, with the decision limit at cTnI >0.34 Pg/L for our 
assay, which we applied in our analyses. The patients’ cTnI levels were classified as 
typical rise, gradual fall, both, or none of these. A cTnI change of >20% from the index 
level was classified as typical rise or fall (95). For lower cTnI index levels, we chose an 
absolute concentration change (delta) between two cTnI measurements of 0.20 Pg/L in 
a setting of typical rise or gradual fall (96).  
 
ECG 
Paper II and Paper III 
ECGs were evaluated in all patients with a clinical presentation consistent with 
myocardial ischemia. The ECGs were analysed retrospectively by the first author 
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blinded to clinical outcome and in accordance with the ECG criteria from the four 
different AMI definitions studied. Patients with ECG changes indicative of AMI but with 
normal or missing troponin measurement were not included in the current 
investigation with one exception, patients with sudden cardiac death. For validation 
purposes a second cardiologist validated randomly extracted ECGs from 100 patients. 
The interpretation of ST-elevation between the two cardiologists differed in <3%.  
 
3.3 Diagnosis 
Paper I  
We defined the first AMI as the first hospitalization with AMI as the main or secondary 
diagnosis, recorded in WENOCARD on condition that no previous AMI had been 
recorded in the registry. To identify and include only incident (first) and not recurrent 
AMI, a period prior to the AMI of seven years (1972-1978) or more without a 
registration of an AMI was required.  
 
Paper II 
Attending physicians set the discharge diagnoses recorded in the hospital’s Patient 
Administrative System. The medical records for all patients with the selected discharge 
diagnoses were reviewed by trained medical students, and data entered into a 
database. The first author reviewed all registered data and classified the AMI diagnoses 
according to the different AMI definitions and subtypes according to the Universal-
2007 definition (74).   
 
Paper III 
In Paper III two cardiologists independently reviewed all registered data and classified 
the AMI diagnoses and AMI types according to the two Universal AMI definitions. The 
classification initially differed in 67 events (4.5%). In all these cases the cardiologists 
agreed after in-depth discussion. 
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3.4 Subtypes of AMI 
Paper II and Paper III 
The Universal 2007 definition and Universal 2012 definition of AMI do not specify 
whether coronary angiography is required to distinguish Type 2 from Type 1 AMI. 
Coronary artery spasm with resulting ischemia and rise in troponin levels is mentioned 
as a mechanism of Type 2 AMIs. However, patients with coronary artery spasm may in 
addition have coronary plaque erosion with resulting intraluminal thrombus. We have 
therefore chosen to interpret Type 2 AMI as an exclusion diagnosis after performed 
coronary angiography, as have others (97). 
 
3.5 Follow up and mortality 
Paper I 
Data on all-cause and diagnosis-specific death were obtained from the Cause of Death 
Registry, Statistics Norway. All surviving patients were followed until 31 December 
2006. 
 
Paper II and Paper III 
Information on all-cause mortality was obtained from the National Population Registry, 
and all patients were followed from admission until death, and 31 December 2011 or 1 
March 2013 respectively. 
 
3.6 Statistical analysis 
Results are shown as numbers and percentages (%), means with standard deviation 
(SD) or median with interquartile range (IQR) for variables not normally distributed. 
We assessed differences in baseline characteristics between groups using X2-test for 
categorical and t-test for continuous variables. A two-sided p-value <0.05 was 
considered statistically significant throughout. 
 
 
 
 36 
Paper I 
In Paper I the patients were separated into three groups representing the study 
periods: 1979–1985, 1986–1993 and 1994–2001, based on data on admission. Survival 
was studied using all-cause death as main endpoint. Survival time was calculated as the 
number of days between the admission date and the date of death, or 31 December 
2006. Kaplan–Meier survival curves were estimated for both sex groups and age groups 
(<60, >60 years). For each sex-age group, the Kaplan–Meier curves were stratified by 
study period, and difference in survival across time periods were tested using the log 
rank test. To provide separate descriptions of the short-term and long-term survival we 
also performed a landmark analysis with prespecified landmarks at day 28 and day 365 
(98). When plotting the survival curves, the analyses were reset at each of the two 
landmark time points. Each analysis included only patients alive at the landmark time 
point. Trends in 28-day, 1-year and 10-year case-fatality rates across the three study 
periods were assessed using logistic regression with period included as a three-level 
covariate with the first period (1979–1985) as the reference level. Cases from 1997–
2001 with less than 10 years of follow-up were excluded in the 10-year case-fatality 
calculations.  
 
Paper II 
In Paper II we chose the first event for the study period as the reference for mortality in  
accordance with other studies (99;100). Difference in short- and long-term mortality 
after AMI between groups was assessed using logistic regression and Cox regression. 
As there was no loss to follow-up and both methods led to the same conclusions, we 
presented the results from logistic regression in order to be able to compare mortality 
at exactly 28 days, 1 year, 5 years and 8 years. We have used McNemar’s test to test the 
differences in number of AMI events explained by the use of the Universal 2007 
definition compared to the WHO 1979 definition, with the WHO 1979 definition as the 
reference definition.  
 
Paper III 
In Paper III differences in baseline characteristics between Type 1 and Type 2 AMI 
were assessed using Chi-square or Fisher’s exact tests for categorical and t-tests for 
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continuous variables. Unadjusted 28 days, 1, 5 and 10 years all-cause mortality rates 
were calculated separately for types of AMI within each of the two definitions.  
 
We used SPSS version 18 and 21 (IBM SPSS Statistics), Stata IC version 12 (StataCorp 
LP), SAS Version 9.1.3 (SAS Institute Inc., Cary, North Carolina, USA) and S-PLUS 7.0 for 
Windows (Insightful Corporation, Seattle, Washington, USA) for statistical analyses.  
 
3.7 Ethics 
The studies were approved by the Regional Committee for Medical and Health 
Research Ethics and conducted in accordance with the Declaration of Helsinki. The 
Data Inspectorate and the Norwegian Directorate of Health gave the necessary 
permissions, including an exemption from the requirement of obtaining patient’s 
consent.  
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4. Summary of results 
4.1 Paper I 
A total of 15873 patient’s admissions with a first or recurrent AMI to Haukeland 
University hospital during 1972-2001 were studied. After censoring 3995 patients 
admissions during the first seven years (1972-1978), the study population consisted of 
11878 patients (4243 women and 7635 men), with a first AMI hospitalized during 
1979-2001 (Figure 6). During the three periods (1979–1985, 1986–1993 and 1994–
2001), mean age at the onset of the AMI in women increased significantly from 73.5 to 
75.2 years (P<0.0001), whereas it was unchanged in men at 66 years. The proportion of 
women was stable at 36% throughout the entire study period. Among the patients 
under the age of 60 years, the proportion of women was approximately 16% 
throughout the study.  
 
 
 
 
 
  
 
 
 
 
Figure 6: Flow chart illustrating selection of patients in paper I. 
 
From 1979–1985 to 1994–2001, unadjusted 28-day case fatality declined from 31.1%  
to 19.8% in men and from 37.3% to 26.8% in women (both, P-trend < 0.0001). 
Unadjusted 10-year case fatality declined from 69.5% to 55.5% in men and from 80.8% 
to 66.1% in women (both, P-trend <0.0001). Landmark analysis demonstrated a 
decline in 1-10 year case fatality, among patients <60 years from 26.1% to 13.8 % in 
men, and from 33.3 % to 6.4 % in women. In patients >60 years, the 28-day, 1-year and 
10-year age-adjusted case fatality rates were significantly lower in women than men.  
 
n = 15873 
Patient admissions with 
a first or recurrent AMI to 
Haukeland University Hospital 
1972-2001 
n = 3995 
Patient admissions 
during the first seven years 
censored (1972-1978) 
n = 11878 
Patients with a first AMI 
1979-2001 
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4.2 Paper II 
The source population consisted of 1997 patient admissions with a diagnosis of AMI 
(815 patient admissions), and additionally 679 patients admissions with at least one 
measurement of elevated cardiac troponin I (cTnI) >0.10 mg/l during the hospital stay, 
but not diagnosed with AMI. After exclusion of 379 patient admissions with measured 
cTnI levels <0.34 mg/l and 124 recurrent admissions during the inclusion period, the 
study population consisted of 1494 patients. Men (n = 974) were younger (mean age 
65.6 years) than women (n = 520, mean age 73.6 years) at admission (p <0.001). Mean 
age, risk factors, clinical status, and treatment varied only slightly according to the 
different AMI definitions. 
 
Figure 7: Flow chart illustrating selection of patients in paper II and paper III. 
 
Applying the WHO 1979 definition resulted in 566 patients with definite AMI among 
the 1494 patients, and this number was used as reference. Excluding possible and 
probable AMIs according to the WHO 1979- and AHA 2003 definitions, the numbers (% 
compared with reference) of AMI were: 455 (-20%) by the original troponin “rise and 
fall” version of the ESC/ACC 2000 definition, 729 (+29%) by the troponin “rise or fall” 
interpretation of the ESC/ACC 2000 definition, 761 (+34%) by the AHA 2003 definition, 
and 743 (+31%) by the Universal 2007 definition (all p values<0.001). Of the 743 
124 patient admissions with
recurrent admissions during 
the study period
379 patient admissions with
maximum cTnI 0.10-0.33 
n = 1076
Patient admissions with cTnI >0.10, 
but without AMI diagnosis
n = 1997
Patient admissions 
with  AMI and/or cTnI >0.10
n = 1618
Patient admissions 
with AMI and/or cTnI >0.34
n = 1494
Patients with a first admission
during the study period
with AMI and/or cTnI >0.34
n = 921
Patient admissions with AMI 
discharge diagnosis (I21 or I22)
 40 
patients with AMIs according to the Universal 2007 definition, a total of 659, 28, 30, 20, 
2, and 4 patients had a type 1, type 2, type 3, type 4a, type 4b, and type 5 AMI, 
respectively. The 30 patients with type 3 AMI died shortly after admission and before 
possible detection of cTnI elevation. 
 
Of the 1494 patients, 777 were classified with a definite AMI according to one or more 
different AMI definitions; 358 according to all four definitions, 375 according to >2 
definitions, and 44 according to one single definition. The remaining 717 patients were 
classified with non-ischemic causes of elevated cTnI levels, such as infections, kidney 
failure, myocarditis and elective cardiac surgery. 
 
4.3 Paper III 
The study population of 1494 patients was identical with the population in paper II 
(Figure 7). After an additional validation by an additional physician 769 patients 
(51.5%) were classified with an AMI event according to the Universal 2007 definition, 
and 760 patients (50.9%) according to the Universal 2012 definition.  
 
Among the 760 patients 685, 27, 28, 13, 3, 0 and 4 patients were classified with Types 
1, 2, 3, 4a, 4b, 4c and 5 AMIs, respectively. Although we observed a trend towards 
younger patients with lower comorbidity classified with Type 2 compared to the Type 
1 AMI, only the proportion of angiography and initiated treatment differed significantly 
between this two types. 
 
The application of the Universal 2012 definition of AMI as compared with the Universal 
2007 definition had no impact on all-cause mortality among the patients with AMI. The 
unadjusted 28 days, 1-year, 5-years and 10-years all-cause mortality according to both 
AMI definitions was 14%, 21%, 35% and 49%. 
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5. Discussion 
This thesis demonstrates a substantial decline in short-term and long-term case fatality 
in patients hospitalized for a first AMI during 1979-2001. The number of AMI events 
however depends on which definition of AMI and biomarker is applied. When the WHO 
1979 definition of AMI with CK-MB mass as biomarker was used as reference, we found 
that applying the ESC/ACC 2000, AHA 2003 and Universal 2007 definitions of AMI with 
cTnI as biomarker resulted in approximately 30% more patients diagnosed with 
definite AMI in the same cohort. The change of AMI definitions had a moderate impact 
on the AMI mortality among hospitalized patients. We observed a minor decrease in 
number of events of AMI and no change in mortality when applying the Universal 2012 
definition of AMI as compared with the Universal 2007 definition. 
 
5.1 Trends in long-term case fatality after a first AMI 
The observed decline in short- and long-term case fatality in patients hospitalized for a 
first AMI during the study period 1979-2001, is in line with other studies (23;52;101). 
However, the observed 28-day case fatality during 1994-2001 of 22% may be 
unexpectedly high compared to randomized trials which report a 28-day case fatality of 
5-6% (37;38). The significant difference is explained by our unselected cohort 
including patients from all departments of the hospital, including those who died soon 
after hospitalization, whereas randomized studies usually recruits patients from 
cardiac units with exclusions due to comorbidity and age ending up with highly 
selected study populations. 
 
5.2 Age, gender and case fatality  
In Paper I we observed that among patients >60 years the survival curves for the three 
time periods may seem paralleled after one year. However, Landmark analysis revealed 
a significant improvement in case fatality in both genders during days 29-365 and 
during 1-10 years after the first AMI, as observed previously in a Nordic study (101). 
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Further, we observed in Paper I a substantial decline in age-standardized case fatality 
rates both among men and women. However, the literature has been conflicting 
regarding short-term prognosis for women compared with men following an AMI. 
Large studies have found no gender differences after adjustment for age and 
comorbidity (102-104), whereas others have reported higher short-term case fatality 
in women (105). However, when we adjusted for age we observed a more favourable 
outcome in case fatality for women >60 years compared with men >60 years already 
after 28 days. In patients <60 years we did not find a significant difference in case 
fatality between women and men. Some studies have found a higher short-term case fatality in 
young women with AMI (106-108), the difference may be explained by a higher prehospital 
death rate among younger men compared with younger women (57;107).  
 
5.3 Changing definitions of AMI 
We observed approximately 30% more AMI events among our study population 
according to the ESC/ACC 2000, AHA 2003, Universal 2007 and Universal 2012 
definitions of AMI as compared with the WHO 1979 definition of AMI. Other studies 
have reported higher number of AMI events with the introduction of the ESC/ACC 2000 
definition, ranging from 4% to 195% relative increase (99;109-114). The newer AMI 
definitions had a moderate impact on the AMI mortality among hospitalized AMI 
patients in our study, which is in line with a recent published study (115). 
 
5.4 Subtypes of AMI 
The introduction of Type 1-5 AMI is important for clinical and epidemiological 
research, especially regarding Type 3 (sudden cardiac death) and Type 4 and 5 (PCI 
and CABG) AMI.  
However, the distinction between Type 1 and Type 2 AMI in the Universal 2012 
definition of AMI is poorly defined and different studies have made different 
interpretation of Type 2 AMI resulting in a proportion of this subtype varying from 
1.6% to 26% (97;116-119). 
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In Paper III we compared our study with a Danish study. They focused on Type 1 and 
Type 2 AMI and established their own criteria for classifying Type 2 AMI due to 
anaemia, shock, bradyarrhythmia, coronary embolus, respiratory failure, ventricular 
tachycardia, hypertensive pulmonary edema and hypertension with left ventricular 
hypertrophy (119). Coronary artery spasm was not defined in this study, which 
included patients with elevated troponin levels, and accordingly excluded Type 3 AMI. 
They found 553 patients with an AMI according to the Universal 2007 definition of AMI, 
397 (72%) patients were classified with a Type 1 AMI and 144 (26%) patients with 
Type 2 AMI. Coronary angiography was performed in 281 patients with Type 1 AMI and 
31 patients with Type 2 AMI, with significant coronary artery disease in 248 and 17 
patients, respectively. 
 
In our study the total of Type 1 and Type 2 AMI was 93% according to the Universal 
2007 definition of AMI compared to 98% in the Danish study. However, the proportion 
of Type 2 AMI was highly different with an occurrence of 4% and 26%, respectively. 
Two main factors are probably responsible for the rather large difference. First, there is 
a difference in patient populations. Our study included patients with Type 3 AMI, 
whereas the other study excluded patients without troponin elevation. Secondly, our 
study had a conservative approach where plaque rupture with intraluminal thrombus 
should be ruled out before classifying an AMI as Type 2. In contrast, the Danish study 
emphasized predefined conditions where there may be an imbalance between oxygen 
demand and supply to the heart, without a requirement for coronary angiography.  
 
Studies of coronary angiography have found no evidence of obstructive coronary artery 
disease among 7-10% patients with STEMI, and among 4-15% patients with NSTEMI 
(120-122). An angiography study demonstrated correlations between obstructive 
coronary disease and Type 1 AMI, and between non-obstructive coronary disease and 
Type 2 AMI (123). However, other recent studies have further examined AMI patients 
with non-stenotic coronary arteries. They found a significant number of plaque rupture 
or coronary ulcerations with computed tomography coronary angiography (CTCA) or 
intravascular ultrasound (IVUS) not detected by angiography (124;125). Thus, AMI 
classified as Type 2 AMI after a normal angiography may still have been due to a 
coronary thromboembolic event. 
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A clear definition of AMI is essential with minimal need for clinical judgement 
(126;127).  One solution of this problem is to develop extensive criteria for Type 2 AMI 
(119;128). However, a distinction between Type 1 and Type 2 AMI does not seem to 
affect the acute treatment of AMI, which relates to the presentation of ST-elevation or 
non-ST-elevation in the ECG (129;130). Secondary prevention of AMI should be 
considered in both types of AMI, because many patients with a Type 2 AMI without 
stenotic coronary arteries at conventional coronary angiography may have plaque 
rupture demonstrated by IVUS and CTCA (124;125). Furthermore, the use of such 
criteria will be time consuming.  An alternative may be to merge the AMI Type 1 and 
Type 2 into one type of AMI, since it will simplify the classification without influencing 
the total number of AMIs. 
 
5.5 Non-ischemic causes of elevated troponin levels 
The Universal 2012 definition of AMI states that cases of non-ischemic causes of 
elevated troponin levels should labelled as myocardial injury, and not as AMI (76). In 
differentiating between AMI and non-ischemic myocardial injury it is important to 
adhere to the main criteria that AMI should be used in a clinical setting of acute 
myocardial ischemia, and the rise and/or fall of cardiac biomarker with at least of; 
ischemic symptoms, new ECG changes, imaging evidence, intracoronary thrombus by 
angiography or autopsy (76). It may be challenging to differentiate non-ischemic 
myocardial injury from Type 2 AMI with poorly defined criteria for Type 2 AMI (128). 
Our conservative approach where plaque rupture with intraluminal thrombus should 
be ruled out before classifying an AMI as Type 2 might simplify this differentiation.  
 
In our hospital based study population, 48% of the patients were classified with non-
ischemic causes of elevated cTnI levels, such as infections, kidney failure, myocarditis 
and elective cardiac surgery, consistent with a similar study (131). Regardless of the 
diagnosis of AMI or non-ischemic myocardial injury, patients with elevated cardiac 
biomarkers have increased short- and long-term mortality compared with patients 
without elevated troponin (128;132). 
 
 45 
5.6 Strength and limitations 
Paper I 
A major strength is the large number of patients studied at a single university hospital 
over a long period of 23 years with a follow up for up to 10 years case fatality, which is 
longer than most other studies. In addition, nation-wide follow-up of all patients by 
linkage to the Cause of Death Registry contributes to that very few patients were lost 
during follow-up. 
 
The WHO definition of AMI was used in the entire study period.  However, there was no 
strict validation of the clinical basis for the AMI diagnosis, and the discharge diagnosis 
of the attending physician was accepted. Troponin was officially implemented in the 
diagnostic setting in 2002, and therefore troponin would not have any influence on the 
incidence of AMI in the study period 1979-2001. The potential bias from improvements 
in emergency care outside hospital, or change in diagnostic criteria, is unknown. 
 
 
Paper II and Paper III 
Paper II is one of few that compare number of AMI events and long-term mortality 
applying four different definitions of AMI. This was further explored in Paper III in the 
same patient cohort where we compared the Universal 2007 and the Universal 2012 
definition of AMI. A major strength in these two papers is the registration of every 
measured troponin value and the precise categorisation of rise or fall of cTnI, as well as 
complete mortality follow up. 
 
Paper II and Paper III have several limitations. First, using clinical judgement in the 
retrospective classification of AMIs according to five different definitions of AMI 
induces some risk of misclassifications. Second, the 4.5% inter-observer variation 
between primary classification by the first cardiologist and additional validation of a 
second cardiologist in Paper III was small, and after in-depth discussion, there was no 
variation left.  The additional validation of AMI events resulted in 769 AMI events 
applying the Universal 2007 definition of AMI in relation to Paper III, compared with 
743 AMI events in the same cohort in relation to Paper II. Third , Type 2 AMI is not well 
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defined in any of the Universal definitions. We applied our own interpretation of Type 
2 AMI, and our results may not apply to other hospital populations. Forth, 137 patients 
had a single elevated cTnI. However, only 16 of these patients were lost as a potential 
Universal 2007 or Universal 2012 definition AMI, due to missing information on 
troponin values from the local hospital. Fifth, we did not examine the patient records of 
all patients who had undergone PCI or CABG during the inclusion period; only patients 
with elevated cTnI levels were included. We may therefore have underestimated the 
number of patients with Type 4 and Type 5 AMI. Sixth, we do not have data on Type 4c 
AMI (restenosis) according to the Universal 2012 definition, these are therefore 
included in the other subtypes of AMI as in the Universal 2007 definition. 
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5.7 Perspectives 
The definition of AMI has been revised several times since the introduction of the first 
definition by the WHO in 1959, due to the advances in biomarkers and cardiac imaging 
(61;63;66;68;73-76). However, the changing AMI definitions have complicated the 
analyses of trends in the number of AMI events and mortality. It is therefore important 
to study the different AMI definitions with respect to number of AMI events and 
mortality.  The definition of AMI should be as simple and clear as possible to facilitate 
clinical practice and research (126;127). It should probably not be changed more 
frequently than necessary, because it takes time before clinicians and researchers are 
familiar with a new definition.   
 
The poorly defined distinction between Type 1 and Type 2 AMI in the Universal 2012 
definition of AMI should be merged or better defined. 
 
We have not known the exact incidence of AMI in Norway, due to lack of a register with 
personal identification numbers. This will be facilitated by the Norwegian 
Cardiovascular Disease Registry and the Norwegian Myocardial Infarction Register, 
established 2012 and 2013 respectively. These registries will provide us with further 
data for prevention, quality improvement and health research (57;133). Myocardial 
infarction is still an important cause of death in Norway and worldwide (55;134;135). 
Although we have seen a decline in incidence and mortality in our country during the 
last decades, recent studies demonstrate a trend towards increasing hospitalization 
rate of AMI in younger persons (52;57;58). Notably, the obesity epidemic is primarily 
influencing young and middle aged subjects, and is expected to promote increase in 
diabetes and a possible increase in AMI (56). This will pose a particular challenge for 
clinical and epidemiological surveillance (136). 
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6. Conclusions 
 
1. Impact on short- and long-term case fatality among patients hospitalized 
with a first acute myocardial infarction during 1979-2001 
There has been a substantial decline in short-term and long-term case fatality in 
patients hospitalized for a first AMI over a study period of 23 years in our 
university hospital. The improvement is observed in both sexes and in young 
and old patients. Women >60 years fare better than men do when we compare 
age-adjusted case fatality rates.  
 
2. Impact of applying four different definitions of AMI on the number of AMI 
events and mortality  
The number of AMI events depends on the definition of AMI and biomarkers. 
When the WHO 1979 definition of AMI with CK-MB mass as biomarker is used as 
reference, applying three newer definitions of AMI with cTnI as biomarker result 
in approximately 30% more patients diagnosed with definite AMI. The change of 
AMI definitions has a moderate impact on the AMI mortality among hospitalized 
patients. 
 
3. Impact of applying the Universal 2012 definition of AMI compared to the 
Universal 2007 definition with respect to number of events, subtypes and 
mortality  
 The change from the Universal 2007 definition to the third Universal 2012 
definition of AMI primarily involve the PCI- (Type 4a) and CABG-related (Type 
5) AMIs, with a minor decrease in number of AMI events and unchanged 
mortality. Because distinction between Type 1 and Type 2 AMI is poorly defined 
in the Universal definition and few patients are diagnosed with Type 2 AMI, one 
may question whether the two definitions should be merged or better defined. 
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